(-0.88%) 4 967.23 points
(0.56%) 37 986 points
(-2.05%) 15 282 points
(0.62%) $83.24
(0.17%) $1.760
(0.36%) $2 406.70
(1.29%) $28.75
(-1.17%) $943.30
(-0.14%) $0.938
(-0.28%) $11.01
(0.55%) $0.808
(-0.96%) $93.00
Live Chart Being Loaded With Signals
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company develops a pipeline of immune modulation based proprietary drug candidates for unmet need, including immuno-oncology, and organ protection and regenerative medicine...
Stats | |
---|---|
Today's Volume | 6 196.00 |
Average Volume | 30 917.00 |
Market Cap | 84.61M |
EPS | £0 ( 2024-03-13 ) |
Last Dividend | £0 ( N/A ) |
Next Dividend | £0 ( N/A ) |
P/E | -2.87 |
ATR14 | £2.70 (2.30%) |
Faron Pharmaceuticals Oy Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Faron Pharmaceuticals Oy Financials
Annual | 2022 |
Revenue: | £0 |
Gross Profit: | £0 (0.00 %) |
EPS: | £-0.590 |
Q2 | 2023 |
Revenue: | £0 |
Gross Profit: | £-149 522 (0.00 %) |
EPS: | £-0.110 |
Q1 | 2023 |
Revenue: | £0 |
Gross Profit: | £0 (0.00 %) |
EPS: | £-0.110 |
Q4 | 2022 |
Revenue: | £0 |
Gross Profit: | £-131 856 (0.00 %) |
EPS: | £-0.140 |
Financial Reports:
No articles found.
Faron Pharmaceuticals Oy
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company develops a pipeline of immune modulation based proprietary drug candidates for unmet need, including immuno-oncology, and organ protection and regenerative medicine. Its lead product candidates are Traumakine, an intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury; and Bexmarilimab, a novel precision cancer immunotherapy candidate for treating solid tumors, non-small cell lung carcinoma, and hematological malignancies. The company also develops Haematokine, a new chemical entity AOC3 inhibitor for the treatment of hematological malignancies and bone marrow. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators